Drive Decisions with Knowledge
Many compounds fail during development due to lack of selectivity and poor understanding of their mechanism of action (MOA). In vitro discovery strategies do not reflect drug targets in their native context. An understanding of drug action across cellular networks uncovers mechanism of action and predicts future safety concerns early in the development process.
Using cutting edge Protein-fragment Complementation Assay technology from Odyssey Thera, Lonza is able to offer profiling services that can shape and influence critical decisions about drug candidates. This unique cellwide analysis platform broadly addresses target classes, signaling pathways and cellular processes, classifying drugs by comparison to an extensive compound database defining MOA and predicting safety threats.
This service delivers:
- Analysis of drug activity for any target class or pathway across cellular systems
- High-content/high-throughput data capture and analysis
- In-depth data interpretation including comparison to an extensive database of known drugs and toxicants
- Improved decision making throughout the development process
Assay Diversity: Unprecedented target class and pathway coverage with proprietary high content assays
Figure 1. Compound profiling panel comprises proprietary assays measuring diverse cellular processes and signalling pathways. Data illuminates compound mechanism of action, cellular selectivity and safety.
Compound mechanisms, selectivity and safety are measured across diverse high-content, biochemical and functional assays
Figure 2. Compound profile showing the activity of Velcade (Bortezomib) across an assay panel. High content assays are quantified by automated image analysis on our proprietary platform. Each red dot represents the fold change in activity (increase or decrease) for an individual cellbased assay. Compound profiles are automatically compared to extensive known drug/toxicant database to identify mechanisms and potential safety issues.
Rapid identification of compound selectivity and safety issues
Figure 3. Proprietary algorithms and an extensive known drug/toxicant database are used in conjunction with compound profiles to define test agent selectivity (y axis) and to define similarity to known toxicants (x axis). Compounds in the upper right quadrant have a high probability of toxicity (small portion of drug database is displayed).
Please contact your Lonza Drug Discovery sales representative or compoundprofiling@lonza.com for further information.
